BELLEVILLE, ON, June 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, hosted a
two-day conference in Toronto this week entitled, "E. coli O157 Vaccine: Added
Value or Added Cost". The audience included veterinarians and representatives
from the food industry: Beef, dairy, and other agricultural commodity
producers.
